the, the, the russian president vladimir printing said months ago is working with a mass to secure the release of is really of stages. concept things rarely from minutes. the orders, the idea of assault and gas off to continue projecting of these by i deal with a mass and respond to the us secretary of state visit to tell of it. so it didn't jump down its own investigation into the north stream. last wild to accept prize winner hash alleges that swedish and danish con suggested in what keep concluded what to do with lead sabotage. the us senate fails to adopt a border secure to build world $118000000000.00, stripping ukraine and israel lump sums of military age at foreign minister. justin

true. del reported, meet personally invited decree, and often access fletcher and hunger for an official reception in september last year. the russian embassy in canada condemned the was all the headlines of our uh website. archie dot com has no stories, so don't forget to check it out. i'd say show i josh, i'll be back at the top of the hour for more headlight, the know diagnosis strikes, fear into the hearts of patients more than the dreaded c word cancer. it is a war we all fear, and yet every day, more of us are forced to face it. unfortunately, it is becoming more and more common as a world health organization hasn't feel that it has overtaken heart disease is the

biggest killer globally, the growth and the incidence of cancer parallels the industrialization and chemical eyes ation of the world. the more developed the country is, the more cancer, there is the higher per capita income, the higher incidence of cancer. i'm crisp and you're watching the cost of everything we're today. we're going to be faced with the cost of cancer. the panther is the 2nd leading cause of death in the us. but luckily, today, many kinds of cancer can be prevented or caught early. leading risk factors for preventable cancers, our smoking, getting too much uv radiation being overweight and drinking too much alcohol. at this point, one and every 3 people, you know, will have cancer in their lifetime, which is a horrifying statistic. breast cancer survival rates go up. so the price tags of

life saving treatments, monthly drug costs may reach a $100000.00, causing money to struggle with the high costs, even worse. others are completely priced out of even the hope for cure the low income families that americans who are uninsured or under insured face medical bills, more than 4 times their annual salaries and simply cannot afford the rising cost of cancer treatments. cancer patients are 2 and a half times more likely to declare bankruptcy and 71 percent are more likely to experience a severe adverse financial event then healthy people. now, in the us alone, over 1900000 new cancer cases were diagnosed in 2023. the average total cost of cancer treatments run in the a $150000.00 range, but it doesn't paint an accurate picture. total out of pocket costs depend on a number of factors, including insurance coverage, the types of cancer and treatment, the frequency of treatment,

and the costs related to the cancer center. key well, therapy is one of the most common cancer treatments. and depending on the drugs and the type of cancer, the average monthly cost of chemo can range from a $1000.00 to $12000.00. if a patient requires 4 rounds of chemo, then that would cost some up to $48000.00 total. we just beyond the average annual income, all their costs associated with cancer include hiring caregivers or a home health aide. transportation lost wages by specialty items such as certain types of food wigs or fertility treatments that can all add up the 4 of the 5 most expensive cancer drugs on the markets or types of amino therapies. these drugs cost as much per month than what the average american makes and a year, which is $52800.00. but i run equi despite the high price tag. the drugs don't work for most patients. a studies showed only 13 percent of patients actually

benefited from these types of treatments. and now today we're joined by doctor has sham posing oncologist at christmas. saint michael on ecology clinic. now dr. which types of cancers are most prevalent on a global scale, and how has this changed over the years? so cancer varies between different populations and every type is a rare and some part of the world. many specific causes are now known um for the large proportion of global variation for common kansas remain on the remains unexplained. considering both sexes, either female, breast, male, prostate, or several categories, most commonly diagnosed cancer over the and over 70 percent of countries. um the, the number of cases had been increasing, but the number of new cases in this had been decreasing over the past 20 years, which is pretty example right. as far as the most common cancer is, it depends on which areas we're talking about. the most common problem in kansas around the gold is breast cancer. the,

the most common cause the depth of cancer around the world as lung cancer is now. and if we're talking about particular regions, mostly north america, uh, north america, uh, a western europe. uh, mostly its uh, female with breast cancer and mostly the most common causes lung cancer. so certain populations in west africa and said that south africa, the most common is cervical cancer. in those reasons for that as far as um, certain places in asia in mongolia most common is liver cancers. and south of japan is stomach cancer, gastric cancer. so all depends, but yeah, that's those are the most common that we see worldwide us. and gladly we are, you know, thankfully there are decreasing cases over the past 1015 years. are there a particular reasons or countries experience a higher incidence? a certain cancers? yeah, pretty much uh, in terms of uh, certain regions, like i said, most highly industrialized countries mostly is for us than uh,

breast cancer as well as by mail, prostate cancer and lung cancer. the reason is because there's better screenings and those countries, um, as far as those other regions i mentioned before, so south africa and western western africa, the higher incidence. and that's from several cancer because there is a lack of screening, a circle cancer. there's a very simple test that we do call the pap smear, which is not developed in those countries. hopefully there be proceeding along as far as mongolia that i mentioned before. there's a high high instance of liver cancer over any other cancer. and the reason is the high rates of hepatitis b and c and liver and alcohol, alcohol consumption, which is a, has a high propensity for developing liver cancer. as far as the south japan, um through there are the most common is gastric cancer. and the reason for that is the smoke meets that they use and the high incidence of h priority, which he will, he will go back to by laurie, which is a bacteria infection which is known to cause stomach cancer. what cultural or

environmental factors might contribute to these regional variances? well, the cultural is pretty much, uh, maintaining a healthy lifestyle. and i think some of the cultures that we see around the world, even including a united states in western europe. the, the, the culture that we see is, you know, less lots of a healthy lifestyle, more propensity to being towards uh, having uh hi. hi saturated set. aside the diets as well as increase to their store, increased amounts of smoking and in those parts of the world. but those are the most common causes of uh uh, uh, of incidence of a lot of those cancer. um, but like i said, mention before 70 percent of them are unexplained, but yeah, those are the culture lifestyles and just sometimes having basic, you know, mentoring needs as can lead to cancer's. unfortunately, in those lower income uh,

lower income countries, they don't have access to health care. they don't have access to screen programs. even so certain parts of united states has no access to screening. either a significant differences in cancer outcomes between high income and low income countries. yeah, overall, although the overall into this case was lower in lower income countries compared with high income countries, the total cancer related mortality is significantly higher and lower income country, especially for people younger than age of 65. and the greater economic impact as a result is premature vitality and loss of yours productivity. it's especially a problem that for these low income countries, i think if 201570 percent of all global debts, triple to non communicable diseases including cancer occurred in lower income countries with nearly 50 percent of debts in lower income countries considered to be premature. so pretty much we're seeing them in the younger populations um just because of the lack of screening and when they catch these certain types of cancers and these lower income countries that are always advance and stage disease locally

advanced disease, where the, the mortality is higher, especially as opposed to patients that people, patients are people in hiring countries have access to screening. they have treated early, they catch that early disease and they survive longer because they're either treated with surgery, radiation or chemotherapy. so although the incidence has higher and higher income countries because of screening, the mortality is higher and lower income countries. and how have the technological advancements such as precision medicine and amino therapy impact of the cost and efficacy of cancer treatments globally. and are there disparities and the adoption of these technologies across different countries? well, with advent of the middle there be, which came about in all certain drugs game and prior to 2012 most come immunotherapy sub game in 2012. there had been for the past 40 years, the precision medicine which is based on something called next generation sequencing or molecular testing in which we could pinpoint and have a predictive,

precise, accurate attack form a attack towards these cancer. so basically what these molecular testing is, precision testing models on or these testing performs is basically a gene panel and. ringback you take, i've done a fi, actionable mutations in which the oncologist can predict a cook could provide a, provide a certain to care a certain type of drug that text a certain attacks the cancer itself. so for since the advent of time, oncology care is basically using conventional chemotherapy which is kind of like a quote unquote shopping approach in which it destroys all cells. it just attacks the dna. and unfortunately, there is severe side effects associated with, with the advent of target. the therapy with for example targeting kinase and heather is basically attacking a certain types of cancer cells or immunotherapy, which makes them unit system hyper vigilant or on mass the tumor. it allows for

better precision guided therapy for cancer and has allowed for higher response rates, longer duration of responses, disease, free survival and, and more importantly, overall survival which has impacted cancer care in the past 20 years. given current trends. what the for see as a future challenges and opportunities in addressing the global impact of cancer, drugs and vaccines are sometimes a little disappointed in cancer diagnosed to a screen equipment in surgical facilities that may be non existent. often cancer patients and low income countries are not diagnosed until disease bids making from treatment less effective and more costly. so those are that mostly the future challenges is how much, you know, one, how much gum regulation prevents for the access to health care and to pretty much the population access to screening and diagnostic testing and allowing the long term treatment for early stage disease. thank you. so much dr. heavy,

but please stick around. the doctor has shown his he must stay with us right after the break and when we come back, not only the patients have to deal with the burden of the disease, but also the burden associated with cancer care. we'll have more after the break, the

result of why it was can be started by live. these can be expanded by a true importance of we can never be of a station that transparency is next for to rejoin. mystic trees then just succeeded in finding the documents that existed in making them available to the public. i mean, what could be more moving box by publishing information and sharing information with the public? he was exercising the right to free speech. he did so in the public interest. so mommy applies tends to me and, and honestly think of late continuously. i know why advice may assume that no one who is the guy that illegal anymore wisely bought. adjustments for to

be on box weighing a 100 me for the ritual. this sense of all we going to let that stay the even one diagnosed early and attacked with the latest treatments. cancer still has the power to kill according to the world health organization, the 3 can. so if that killed the most people worldwide in 2020, we're lung cancer. at 1800000, that's colorado counts or 916000 deaths and liver cancer at 830000 deaths. prostate cancer and breast cancer on the other hand are among the most common and prevalent types of cancer. now a cancer diagnosis can affect life in many ways for both the people with cancer and for their families. in addition to the many physical and emotional challenges,

many people worry about how they will pay for the treatment or what will happen if they aren't able to work or need to make a change and how they work. in 2019, the national patient economic burden associated with cancer care was estimated to be $21000000000.00. this estimate includes out of pocket cost, at $16200000000.00 and patient time cost of $4900000000.00 without insurance. the national cancer institute found that the average cost of medical care and drugs to be over $42000.00 in a year after a cancer diagnosis. they tend to have poor access to care poor cancer outcomes and experienced a greater amount of financial hardship. they also tend to be diagnosed with cancer at a late stage when the disease is also harder to treat. of the global oncology market was valued at over $200000000000.00 in 2022. and this is expected to reach over $400000000000.00 by 2032. and unfortunately therapies now routinely cost

more than $100000.00 per year. and many of these therapies are often mis prescribed . a study found that physicians who consistently put pharmaceutical money in their bank accounts or more likely to prescribe that company struct. meanwhile, on colleges are hesitant to prescribe generics because such prescriptions cost them money. oncologist receive a 6 percent markup, meaning when they infuse a patient with a $10000.00 monthly course, a chemo, their practice yields an extra $600.00. if they prescribe generic, they would be out most of that extra money. so unfortunately, while you're forced to trust that your physician has your best interest at heart, that may not always be the case. so for this and more, let's bring in again. doctor has sean housing oncologist at christmas, same michael oncology clinic. now what factors contributed to the high cost

associated with the different types of cancer treatments? so, the factors, um, basically, and i'm pretty much going to be talking about mostly united states, i guess because i, i'm well versed in that. but the health care delivery systems are 3rd party pairs private or government, which covers the cost of cancer treatment in ensure public has a presume and possibly go right across all approved drugs. which is a debate with himself. the starting price of cancer drugs have at least 3 major problems. first, absolute crossing cost to society will become increasingly on affordable um to with some of the cancer drugs that are not the approved basically through regulations that leads to increased costs, which is out of pocket for the patient. and um and um, and basically new drugs are unpredictable and geographically viable as a result, charge payments in need to be meaningful increase to keep up with the costs of care . and basically, off label use may use expenditures and drugs that offer little to know,

express advocacy, which we don't know about the, and basically other factors are basically the patent system which leads to a monopoly. this is doing parts of biological conducting and cancer. basically, certain drugs attacks are in parts of the dna. certain companies can have a pain on it and that could lead to less innovation. and just having one company control that drug in particular. and this is due basically to regulation high cost of developing the drugs. so basically in order to meet certain regulations, the drug companies have to spend a certain, uh, certain amount of money to go from bench research to actual clinical trials which leads to a problem with that itself. so those are the multiple, multiple factors that we see that are um, impacting the impacting kendra care and access to cancer care. can you break down the typical expenses involved in cancer treatment, including medication surgeries and other interventions?

well, well, good talking to in terms of cancer drugs basically in early 2000 and ten's, you know, cancer care for certain medications to undergo chemotherapy was about $1500.00, you know, in terms of medication out of pocket for the patient. now in 2020 our, you know, from the, from the studies that we have from 2020, nothing after 2020 that are definite, but the average cost for a person to undergo keyma therapy in terms of medications. doctors appointments, you know, transportation, all social economic factors basically went from $1500.00 to $5000.00. now, as far as chemo therapy goes for a certain drug, one type of amino therapy, 3 doses are equivalent to $12000.00, which is pretty, pretty high. for surgery that would be almost as cost of a surgery or even radiation therapy itself. these costs of these newer drugs which

are amazing in terms of breakthrough technology and increasing laser light survival in terms of cancer patients. unfortunately, these are highly expensive drugs and one because of like i mentioned before, monopoly government regulations which increased costs from the pharmaceutical companies and the lack of a coverage from insurance insurance is so hopefully the answer this question and how effective is health insurance and covering the costs of cancer treatments and what are the gaps in coverage that patients often experience? well unfortunately, like i mentioned before, the insurance is don't cover the costs of the drug. the reason one is if a drug is shown to be applications in a certain type of cancer, it might be lagging in time for at the approval, regulation and insurance is loved to go on to the approval. if it's not updated proof insurance will not cover it. regardless, it's a like saving drug, even though it's been proven. and there's been multiple randomized based phase 3

trials in terms of the drugs showing the application. insurances won't cover it. number 2, some are certain insurance companies won't cover it if the drug is not listed in ncc and guidelines, which is and then our guidelines are bible for treating certain types of cancer. so basically the insurance won't cover it or they won't cover fully unless it's on that, and that takes time itself to be listed on ncc and enter this as i'm talking in regards united states practice is another thing would be a cancer pathway. basically these pathways are offered by certain a certain organizations of certain kinds organizations. and if there's a list in the pathway, the insurance doesn't cover it. and then of course you have medicare with certain type of coverage, 80 percent, which a supplemental is needed to cover the rest. so sometimes it covers all, sometimes it covers non, it's very light bile in terms of you know, what kind of the costs uh, does the patient incur from the out of pocket as opposed with the insurance covers

. and to what extent are generic drugs and bios similar as contributing making cancer treatment is more affordable. so they contribute a significant portion. the bio similar is, are basically just another synthetic version of the drug itself. and it's allow, allows for affordable fordable purchases from hospital or health care organizations in which they're able to purchase the drugs in an affordable manner. it's still quite expensive, but it has allowed for some hospitals and some private organizations to stay afloat because of the specific variance and it bypasses the monopoly of certain drug companies. unfortunately, there's been a influx of bio similar uh, unfortunate or certain insurance companies which will purchase a certain type of bias on there. and then there's the hospital organization or the private organization, which only allows certain, formulated by similar. so there's head to head, you know, always battling getting authorization and payment when dealing with different types

of insurance and different types of health care organizations. um yeah, it's, it's label but does it improve a cheaper for. ready health care? yes, absolutely. for certain types of patients and certain types of insurance is here in united states. either barriers or challenges in the adoption of generic alternatives. and how can these be addressed? basically, the barriers mostly is federal regulations at the approval for certain drugs. those are the biggest barriers because if they don't get their approval, if they don't have a certain regulation to go from a bench research to clinical face studies involving humans, then that that can lead to huge barriers going developing of a certain types of drugs, but also allow it to be affordable and covered by in certain insurances. so mostly it's government regulation and how it can be addressed is basically the uh, um, voting for the proper uh, regulations in the escalating the regulations on certain types of parts of the

company and the regulating certain of to allow for a better open market. and for less of ultimately about creating cancer drugs and the pharmaceutical industry contributed to making cancer drugs more affordable without compromising innovation. yes, they can. um, if the, you know, the certain rules on patents in terms of one particular drug company, i know of only allowing to access that certain type of drugs allowing for a generic to be brought about more bio symbol. there's that could, you know, lead to that. um, allowing less regulation in terms of research and making them more affordable for certain pharmaceutical companies instead of they're allowing to, you know, increase the price of certain drugs based off, you know, what they're, what they're doing. so those are the types of you know, innovations that will allow to affordable access and health care. are there existing models or practices that demonstrate a balance between profitability and accessibility?

i literally touch on this basically clinical pathways and basically uh, health care teams are a comprehensive cancer organization. so basically health care package pathways are a pathway that was developed by the organization in terms of how to treat certain cancers. and which pathway allows you know, which way the physician or the clinician will allow to go to treat the patient. basically it's a standard of care for certain types of cancer patients. for example, if you have an early stage breast cancer, you want to go down this testing pathway. and if this test turns out to be positive, you go down that pathway and negative turn on the best and it leads you to the proper treatment. and insurance is our start to recognize that more and starting to approve it based on those pathways and multiple different organizations of different pathways, but mostly generally the same. so the. ready pathway is allowed to be is allow for less spending because they were approved and less for less error in terms of patient care. and the other thing i mentioned was the comprehensive cancer team. so basically, instead of the condition taken on the burden of being the social worker,

the physical therapy is the dietician nutritionist, we have nutritionist, we have physical therapist, we have social workers, we have um, nurses, we have oral, we have certain pharmacist on the team. and as a team we cater to that one patient and we all focus on our respective specialities, and that has led to less hospitalizations, less emergency room visits in the, in the 1st year of kendrick treatment. so very common thing is for patients who are under the chemo therapy or amino therapy, or any type of targeted therapy, 70 percent of them end up in the emergency room. and that's from a lack of education, or lack of access to certain specialties. and basically that could save up to $200000.00 a year for one patient. so those are the 22 mortality is that i see in my mind that have demonstrated a balance between profitability, accessibility for treatment. thank you so much,

doctor has been for all your time today. cancer continues to be in elusive disease as myriads of mutations exist. every cancer is caused by a different set of mutations, and as the tumor grows more and more mutations accumulate. this means that every tumor has an individual set of mutations. so a drug that works for one patient might have absolutely no effect on another. it is not a single a disease, but rather a group of diseases with more than a 100 different types of cancers. they're also caused by different things, so no one strategy can prevent them. while we may never be able to completely cheer, cancer scientists are optimistic that vaccines, personalized medicines and smart lifestyle choices will help to prevent and treat a much greater proportion of cases than currently today. i'm christy, i thanks for watching and we'll see you right back here next time on the cost of everything. the

parts are expensive and i'm here to plan with you whatever you do. do not watch my new show seriously. why watch something that's so different opinions that he won't get anywhere else. welcome to please or do they have the state department, the c i a weapons makers, multi 1000000000 dollar corporations. choose your fax for you. go ahead, change and whatever you do. don't want my show stay main street because i'm probably going to make you uncomfortable. my show is called stretching time. but again, you probably don't wanna watch it because it might just change the way you so

many people questioned that name was true, provocative. collateral or murder instead of collateral damage the feel for mission . but as a former marine company commander, i knew enough about war law launch of war to an owner. that was in fact, or there is no video of more market in history in the public domain. there is no video type that shows how a country lot in the united states has wage war. there's nothing out there that is so on. fine east that is on census, that shows what was in the modern era is really like nothing. and that's why the us government doesn't want it in the, in a court room where they want to try to truly in a sense that's why it's not part of the environment of going.